奶奶的牛
2020-07-15
恭喜又一老千股上市
科创板君实生物较开盘价跌30% 股票临时停牌
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":941381079,"tweetId":"941381079","gmtCreate":1594801992491,"gmtModify":1704206876386,"author":{"id":3474596929652921,"idStr":"3474596929652921","authorId":3474596929652921,"authorIdStr":"3474596929652921","name":"奶奶的牛","avatar":"https://static.tigerbbs.com/c8007f2519d56a428612e5ed64e0ebff","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>恭喜又一老千股上市</p></body></html>","htmlText":"<html><head></head><body><p>恭喜又一老千股上市</p></body></html>","text":"恭喜又一老千股上市","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/941381079","repostId":2051001444,"repostType":2,"repost":{"id":"2051001444","kind":"news","pubTimestamp":1594795500,"share":"https://www.laohu8.com/m/news/2051001444?lang=&edition=full","pubTime":"2020-07-15 14:45","market":"hk","language":"zh","title":"科创板君实生物较开盘价跌30% 股票临时停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2051001444","media":"新浪财经","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 新浪财经讯 7月15日消息,君实生物今日在科创板上市,截至发稿,股价涨172.43%,较开盘价跌30%,股票临时停牌,成交","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/newchart/png/min/new_min/n/sh688180.png\"/>\n</div>\n<div>\n<div>\n<span>热点栏目</span>\n<s></s>\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n</div>\n客户端\n</div>\n</div>\n<p> <a href=\"https://laohu8.com/S/SINA\">新浪</a>财经讯 7月15日消息,<span><a href=\"https://laohu8.com/S/01877\">君实生物</a></span><span></span>今日在科创板上市,截至发稿,股价涨172.43%,较开盘价跌30%,股票临时停牌,成交额超71亿。</p>\n<p> 招股书显示,此次<a href=\"https://laohu8.com/S/688180\">君实生物</a>首次公开发行A股募集资金净额为44.97亿元人民币,其中计划12亿元用于创新药物研发,7亿元用于公司在<span><a href=\"https://laohu8.com/S/600848\">上海临港</a></span><span></span>的产业化项目,8亿元用于偿贷及补充流动性。</p>\n<p> 资料显示,君实生物成立于2012年12月,是一家创新驱动型生物制药公司,核心产品之一JS001已获批上市,用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤,目前正在开展适应症拓展的临床试验,UBP1211(修美乐生物类似药)已提交NDA并获受理,JS002(重组人源化抗PCSK9单抗注射液)正在开展临床II期试验。</p>\n<p> 君实生物预计2020年1-6月业绩,归属于母公司股东净利润亏损6.81亿元至5.63亿元,同比下降133.97%至93.46%。特瑞普利单抗(PD-1)仍是其“烧钱”的主要产品,由于该产品于去年2月起刚开始实现销售,销售收入尚不能覆盖研发费用等支出。</p>\n<p> 君实生物首席执行官<a href=\"https://laohu8.com/S/02331\">李宁</a>表示:“科创板的设立为君实生物在内的致力于创新发展的医药企业提供了一个良好的资本支持平台和展示窗口。此次登陆科创板是君实生物又一个重要的里程碑,健康持续的融资渠道将助力我们快速推进管线上的创新产品,同时加强与国内外合作伙伴的联合创新。”</p>\n<div>\n</div> <div>\n</div>\n<div>\n<div><img src=\"http://n.sinaimg.cn/finance/cece9e13/20200514/343233024.png\"/></div>\n<div>海量资讯、精准解读,尽在新浪财经APP</div>\n</div>\n<p>责任编辑:田原 </p>\n</div></body></html>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科创板君实生物较开盘价跌30% 股票临时停牌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科创板君实生物较开盘价跌30% 股票临时停牌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-07-15 14:45 北京时间 <a href=https://finance.sina.com.cn/stock/gujiayidong/2020-07-15/doc-iivhuipn3143918.shtml><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 新浪财经讯 7月15日消息,君实生物今日在科创板上市,截至发稿,股价涨172.43%,较开盘价跌30%,股票临时停牌,成交额超71亿。\n 招股书显示,此次君实生物首次公开发行A股募集资金净额为44.97亿元人民币,其中计划12亿元用于创新药物研发,7亿元用于公司在上海临港的产业化项目,8亿元用于偿贷及补充流动性。\n ...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/gujiayidong/2020-07-15/doc-iivhuipn3143918.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","relate_stocks":{"688180":"君实生物","01877":"君实生物"},"source_url":"https://finance.sina.com.cn/stock/gujiayidong/2020-07-15/doc-iivhuipn3143918.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2051001444","content_text":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 新浪财经讯 7月15日消息,君实生物今日在科创板上市,截至发稿,股价涨172.43%,较开盘价跌30%,股票临时停牌,成交额超71亿。\n 招股书显示,此次君实生物首次公开发行A股募集资金净额为44.97亿元人民币,其中计划12亿元用于创新药物研发,7亿元用于公司在上海临港的产业化项目,8亿元用于偿贷及补充流动性。\n 资料显示,君实生物成立于2012年12月,是一家创新驱动型生物制药公司,核心产品之一JS001已获批上市,用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤,目前正在开展适应症拓展的临床试验,UBP1211(修美乐生物类似药)已提交NDA并获受理,JS002(重组人源化抗PCSK9单抗注射液)正在开展临床II期试验。\n 君实生物预计2020年1-6月业绩,归属于母公司股东净利润亏损6.81亿元至5.63亿元,同比下降133.97%至93.46%。特瑞普利单抗(PD-1)仍是其“烧钱”的主要产品,由于该产品于去年2月起刚开始实现销售,销售收入尚不能覆盖研发费用等支出。\n 君实生物首席执行官李宁表示:“科创板的设立为君实生物在内的致力于创新发展的医药企业提供了一个良好的资本支持平台和展示窗口。此次登陆科创板是君实生物又一个重要的里程碑,健康持续的融资渠道将助力我们快速推进管线上的创新产品,同时加强与国内外合作伙伴的联合创新。”\n\n \n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:田原","news_type":1},"isVote":1,"tweetType":1,"viewCount":1125,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":18,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/941381079"}
精彩评论